About Alpha-1 Antitrypsin Deficiency–Associated Liver Disease

As you may know, Alpha-1 Antitrypsin Deficiency (AATD) is an inherited condition that can cause damage to the liver and/or the lungs.^Footnote1 It is passed down from parents to their children. Liver disease associated with AATD (also known as Alpha-1 Liver Disease^Footnote2) is caused by abnormal AAT protein building up in the liver.^Footnote3 Not everyone who produces abnormal AAT protein develops Alpha-1 Liver Disease; but in those who do, the build-up of abnormal AAT triggers liver damage.^{Footnote3,Footnote4} This can lead to the development of fibrosis, which is the formation of scar tissue in the liver, and that may progress to cirrhosis, a late stage of scarring of the liver, potentially necessitating a liver transplant.^{Footnote3,Footnote4,Footnote5,Footnote6}

Currently, there is no approved treatment option for Alpha-1 Liver Disease.^Footnote2

By taking part in a study that is evaluating an investigational study drug designed to target the cause of Alpha-1 Liver Disease, participants in The Redwood Study could make a difference in the lives of others who have or may be diagnosed with Alpha-1 Liver Disease in the future. If you’re interested in this important research, we invite you to click the button below to answer some questions and see if you may qualify for participation.

See if you may qualify